厄洛替尼和贝伐珠单抗治疗非小细胞肺癌（NSCLC）患者的 VeriStrat 分类器用于生存和进展时间。
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
机构信息
Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States.
出版信息
Lung Cancer. 2010 Sep;69(3):337-40. doi: 10.1016/j.lungcan.2009.11.019. Epub 2009 Dec 29.
Abstract
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.
摘要
我们以盲法将一种经过验证且市售的针对厄洛替尼治疗后生存的血清蛋白质组分类器（VeriStrat）应用于接受厄洛替尼联合贝伐珠单抗治疗的复发性晚期 NSCLC 患者治疗前的预处理血清中。我们发现，VeriStrat 可以将这些患者分为两组，其结果明显更好或更差，并且可能使患者更合理地选择可能从这种昂贵且潜在毒性的治疗方案中获益的患者。
相似文献
1
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.厄洛替尼和贝伐珠单抗治疗非小细胞肺癌（NSCLC）患者的 VeriStrat 分类器用于生存和进展时间。
Lung Cancer. 2010 Sep;69(3):337-40. doi: 10.1016/j.lungcan.2009.11.019. Epub 2009 Dec 29.
2
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.贝伐单抗联合化疗或厄洛替尼与单纯化疗相比治疗复发或难治性非小细胞肺癌的疗效和安全性II期研究
J Clin Oncol. 2007 Oct 20;25(30):4743-50. doi: 10.1200/JCO.2007.12.3026. Epub 2007 Oct 1.
3
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.通过质谱分析进行分类能够准确且可靠地预测接受含厄洛替尼方案治疗的非小细胞肺癌患者的预后。
J Thorac Oncol. 2009 Jun;4(6):689-96. doi: 10.1097/JTO.0b013e3181a526b3.
4
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.VeriStrat(®) 在接受厄洛替尼和索拉非尼治疗的晚期 NSCLC 患者中具有预后价值。
Br J Cancer. 2012 Nov 20;107(11):1820-5. doi: 10.1038/bjc.2012.470. Epub 2012 Oct 18.
5
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.厄洛替尼单药或联合贝伐珠单抗作为 EGFR 突变的晚期非鳞状非小细胞肺癌患者的一线治疗（JO25567）：一项开放标签、随机、多中心、Ⅱ期研究。
Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27.
6
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.贝伐珠单抗联合厄洛替尼对比厄洛替尼单药治疗标准一线化疗失败的晚期非小细胞肺癌的疗效（BeTa）：一项双盲、安慰剂对照、III 期临床试验。
Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X.
7
8
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.回顾性评估一项三期研究中的血清蛋白质组学检测，该研究比较了厄洛替尼联合安慰剂与厄洛替尼联合替沃扎尼（MARQUEE）治疗既往治疗的晚期非小细胞肺癌患者的疗效。
Oncologist. 2019 Jun;24(6):e251-e259. doi: 10.1634/theoncologist.2018-0089. Epub 2018 Aug 23.
9
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.VeriStrat® 对厄洛替尼和贝伐珠单抗一线治疗的晚期非小细胞肺癌患者具有预后价值：SAKK19/05 和 NTR528 的汇总分析。
Lung Cancer. 2013 Jan;79(1):59-64. doi: 10.1016/j.lungcan.2012.10.006. Epub 2012 Nov 1.
10
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.贝伐珠单抗联合厄洛替尼治疗血清蛋白质组学评估的转移性非鳞状非小细胞肺癌的 II 期研究。
Lung Cancer. 2013 Mar;79(3):307-11. doi: 10.1016/j.lungcan.2012.12.005. Epub 2012 Dec 25.
引用本文的文献
1
Semi-Quantitative MALDI Measurements of Blood-Based Samples for Molecular Diagnostics.基于基质辅助激光解吸电离的血液样本半定量分子诊断检测。
Molecules. 2022 Feb 1;27(3):997. doi: 10.3390/molecules27030997.
2
Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial.循环肿瘤细胞作为微小残留病的一种工具可预测肺癌复发：一项纵向前瞻性试验。
Diagnostics (Basel). 2020 Mar 6;10(3):144. doi: 10.3390/diagnostics10030144.
3
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.在不适合一线铂类化疗的晚期非小细胞肺癌患者中，VeriStrat 检测的临床作用。
Eur J Cancer. 2019 Oct;120:86-96. doi: 10.1016/j.ejca.2019.07.025. Epub 2019 Sep 6.
4
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.基于血清的 VeriStrat® 检测与非小细胞肺癌患者的促炎反应物和临床结局相关。
BMC Cancer. 2018 Mar 20;18(1):310. doi: 10.1186/s12885-018-4193-0.
5
Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.癌症中血清聚糖岩藻糖基化、β1-4 分支、β1-6 分支和 α2-6 唾液酸化的阶段依赖性、细胞起源独立性和预后能力。
J Proteome Res. 2018 Jan 5;17(1):543-558. doi: 10.1021/acs.jproteome.7b00672. Epub 2017 Nov 21.
6
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.基于质谱的血清肽组学分析能够准确、可靠地预测晚期肺腺癌患者培美曲塞联合铂类化疗的疗效。
PLoS One. 2017 Jun 8;12(6):e0179000. doi: 10.1371/journal.pone.0179000. eCollection 2017.
7
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.一线接受标准化疗的晚期非鳞状非小细胞肺癌患者的血清蛋白质组学检测
Br J Cancer. 2017 Jan 3;116(1):36-43. doi: 10.1038/bjc.2016.387. Epub 2016 Nov 29.
8
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.贝伐单抗联合厄洛替尼与单用贝伐单抗或厄洛替尼治疗非小细胞肺癌的疗效和安全性：一项系统评价和荟萃分析。
BMJ Open. 2016 Jun 30;6(6):e011714. doi: 10.1136/bmjopen-2016-011714.
9
Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.血清蛋白质组学检测及合并症指数在多样化肺癌人群中的预后价值
Anticancer Res. 2016 Apr;36(4):1759-65.
10
SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.SWOG S0709：厄洛替尼对比厄洛替尼联合卡铂/紫杉醇用于经血清蛋白质组学分析筛选出的晚期非小细胞肺癌且体能状态受损患者的随机II期试验。
J Thorac Oncol. 2016 Mar;11(3):420-5. doi: 10.1016/j.jtho.2015.11.003. Epub 2015 Dec 25.
本文引用的文献
1
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.通过质谱分析进行分类能够准确且可靠地预测接受含厄洛替尼方案治疗的非小细胞肺癌患者的预后。
J Thorac Oncol. 2009 Jun;4(6):689-96. doi: 10.1097/JTO.0b013e3181a526b3.
2
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.接受或不接受贝伐单抗化疗的非小细胞肺癌患者的细胞黏附分子、血管内皮生长因子和碱性成纤维细胞生长因子——一项东部肿瘤协作组研究
Clin Cancer Res. 2008 Mar 1;14(5):1407-12. doi: 10.1158/1078-0432.CCR-07-1154.
3
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.多西他赛与长春花生物碱类化疗用于晚期非小细胞肺癌一线治疗的比较：七项随机临床试验的荟萃分析
J Thorac Oncol. 2007 Oct;2(10):939-46. doi: 10.1097/JTO.0b013e318153fa2b.
4
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.贝伐单抗联合化疗或厄洛替尼与单纯化疗相比治疗复发或难治性非小细胞肺癌的疗效和安全性II期研究
J Clin Oncol. 2007 Oct 20;25(30):4743-50. doi: 10.1200/JCO.2007.12.3026. Epub 2007 Oct 1.
5
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.质谱分析用于对接受表皮生长因子受体酪氨酸激酶抑制剂治疗后的非小细胞肺癌患者的临床结局进行分类：一项多队列跨机构研究。
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195.
6
Bevacizumab in the treatment of non-small-cell lung cancer.贝伐单抗治疗非小细胞肺癌
Oncogene. 2007 May 28;26(25):3691-8. doi: 10.1038/sj.onc.1210366.
7
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.单独使用紫杉醇-卡铂或联合贝伐单抗治疗非小细胞肺癌。
N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884.
8
Erlotinib in previously treated non-small-cell lung cancer.厄洛替尼用于既往接受过治疗的非小细胞肺癌。
N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753.
9
Angiogenesis and lung cancer: prognostic and therapeutic implications.血管生成与肺癌：预后及治疗意义
J Clin Oncol. 2005 May 10;23(14):3243-56. doi: 10.1200/JCO.2005.18.853.
10
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.一项I/II期试验，评估抗血管内皮生长因子单克隆抗体贝伐单抗联合HER-1/表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼用于复发性非小细胞肺癌患者的疗效。
J Clin Oncol. 2005 Apr 10;23(11):2544-55. doi: 10.1200/JCO.2005.02.477. Epub 2005 Mar 7.
Zotero 插件